Artrya (AYA) H1 2026 earnings summary

Executive summary

• Transitioned from development to commercial operations, securing first U.S. commercial customers and generating initial U.S. revenues for SalixⓇ platform and modules.

• Achieved FDA 510(k) clearance for SalixⓇ Coronary Plaque module, enabling real-time detection and new revenue streams.

• Signed long-term commercial agreements with three major U.S. hospital systems, establishing a foundation for recurring subscription and fee-per-scan revenues.

• Advanced SAPPHIRE Study with six high-volume U.S. hospital systems to support clinical adoption and reimbursement.

• Completed a successful A$80 million capital raise to fund U.S. commercialization and operational scale-up.

Financial highlights

• Net loss for the half-year was $10.743m, up from $7.441m in the prior year period, driven by increased commercial and regulatory activities and a $2.223m non-cash charge from option vesting.

• Subscription revenue was $68k, with reported revenue of $14k after non-cash adjustments.

• Cash and term deposits totaled $76.67m at 31 December 2025, up from $11.48m at 30 June 2025.

• Net operating cash outflow was $10.877m, reflecting investment in R&D and commercialization.

• Basic and diluted loss per share were (8.54) cents, compared to (9.12) cents in the prior period.

Outlook and guidance

• Full integration of SalixⓇ platform across all three U.S. customers targeted for early FY27.

• FDA clearance and commercial launch of SalixⓇ Flow module expected in 2026, anticipated to drive further revenue growth.

• SAPPHIRE Study commencement planned for mid-2026, expected to generate clinical evidence supporting broader adoption.